FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2112683927> ?p ?o ?g. }

• W2112683927 endingPage "72" @default.
• W2112683927 startingPage "71" @default.
• W2112683927 abstract "A number of drugs in clinical use, including some antimicrobial agents, are associated with prolongation of the QT interval and the associated ventricular arrhythmia torsades de pointes (TdP) [Vandenberg et al. 2001; Yap and Camm, 2003; Bril et al. 2010]. Although typically the incidence of TdP with particular drugs is low, the potential hazard is high as TdP either (usually) spontaneously resolves into sinus rhythm or degenerates into potentially fatal ventricular fibrillation. Consequently, to maximize safety in both drug development and in the use of existing drugs, it is important to establish factors that may exacerbate QT-interval prolongation and liability towards TdP with drugs.Some macrolide antibiotics have been associated with TdP [Bril et al. 2010; Shaffer et al. 2002]. Clarithromycin is one such drug [e.g. Gysel et al. 2013; Vieweg et al. 2013]. A recent paper in this journal reported major risk factors from the evaluation of 21 case reports of TdP associated with clarithromycin use [Vieweg et al. 2013]. These included female sex (the majority of identified cases were in women), old age and the presence of heart disease [Vieweg et al. 2013]. Some patients received other QT interval-prolonging drugs and/or presented with hypokalaemia, and three patients had evidence of congenital long QT syndrome [Vieweg et al. 2013]. These factors are concordant with known risk factors for drug-induced QT prolongation and TdP [Vandenberg et al. 2001; Yap and Camm, 2003; Bril et al. 2010]. In this letter, we wish to highlight a potential novel modifier of QT prolongation with clarithromycin, on the basis of a recent in vitro investigation of the drug’s actions [Du et al. 2013].Most drugs associated with QT-interval prolongation and TdP share a common action of pharmacological inhibition of the cardiac rapid delayed rectifier potassium current (IKr), which plays an important role in regulating ventricular electrical repolarization [Vandenberg et al. 2001; Yap and Camm, 2003; Hancox et al. 2008]. The pore-forming subunit of IKr channels is encoded by the human ether-a-go-go related gene (hERG) and recombinant hERG channels are widely used to evaluate the propensity of drugs to inhibit IKr [Vandenberg et al. 2001; Yap and Camm, 2003; Hancox et al. 2008]. Clarithromycin is known to produce pharmacological inhibition of hERG [Vieweg et al. 2013]. In addition, the potency of clarithromycin inhibition of hERG has been shown to be enhanced by a mutation to the KCNE2 gene found in a patient with clarithromycin-induced QT prolongation and TdP [Abbott et al. 1999]. The KCNE2 protein can complex with hERG and is a putative molecular partner for hERG in forming IKr channels [Abbott et al. 1999]. The Q9E KCNE2 mutation increases the potency of clarithromycin’s action on hERG [Abbott et al. 1999], thereby exacerbating delayed ventricular repolarization with the drug. We have investigated whether a related protein, KCNE1, can modify hERG pharmacology and our results in respect of clarithromycin suggest that it can [Du et al. 2013].KCNE1 is a small transmembrane protein most well known as a molecular partner of KCNQ1 to form ‘IKs’ potassium channels in the heart, with loss-of-function KCNE1 mutations responsible for the LQT5 form of congenital long QT syndrome [Modell and Lehmann, 2006]. However, KCNE1 appears also able to complex with hERG and thereby has potential to influence IKr [McDonald et al. 1997; Du et al. 2013]. We investigated the effects of two KCNE1 mutations (A8V and D76N, respectively in the N and C termini) and one polymorphism (D85N in the C terminus) on the sensitivity of the hERG current to pharmacological blockade [Du et al. 2013]. Clarithromycin sensitivity of hERG was measured through patch-clamp recordings from hERG co-expressed with wild-type or variant KCNE1 in human embryonic kidney (HEK293) cells [Du et al. 2013]. The half-maximal inhibitory concentration (IC50) for hERG current inhibition with A8V KCNE1 co-expression was raised nearly two-fold compared with that of wild-type KCNE1 (80.26 ± 9.20 µM versus 40.85 ± 4.39 µM, respectively), whilst both D76N and D85N KCNE1 showed lower IC50 values (14.81 ± 6.76 µM and 27.48 ± 6.77 µM, respectively) [Du et al. 2013]. Thus, two KCNE1 variants conferred increased sensitivity to clarithromycin upon hERG, whilst one resulted in decreased sensitivity to the drug [Du et al. 2013].The significance of these findings is that it is possible that individual variation in KCNE1 could feasibly influence cardiac sensitivity to clarithromycin through influencing sensitivity of IKr/hERG to pharmacological blockade (additional to any effect of KCNE1 variation on the IKs channel, which itself may influence net available repolarizing potassium current). A recent candidate gene survey found the D85N KCNE1 polymorphism in 8.6% of drug-induced long QT syndrome cases, compared with less than 2% of controls [Kaab et al. 2012], with other smaller studies also providing evidence of an association [Paulussen et al. 2004; Lin et al. 2012]. This association underscores the potential value of genetic screening in drug-induced long QT syndrome/TdP, whilst our recent data on clarithromycin highlight a potential new mechanism for individual variation in clarithromycin sensitivity [Du et al. 2013]." @default.
• W2112683927 created "2016-06-24" @default.
• W2112683927 creator A5037737415 @default.
• W2112683927 creator A5043271142 @default.
• W2112683927 creator A5076411219 @default.
• W2112683927 creator A5078431481 @default.
• W2112683927 creator A5090269232 @default.
• W2112683927 date "2014-02-17" @default.
• W2112683927 modified "2023-09-23" @default.
• W2112683927 title "A novel genetic modifier for clarithromycin-related cardiac arrhythmia risk?" @default.
• W2112683927 cites W1640055584 @default.
• W2112683927 cites W1997329834 @default.
• W2112683927 cites W2012930217 @default.
• W2112683927 cites W2019973925 @default.
• W2112683927 cites W2039230012 @default.
• W2112683927 cites W2046995007 @default.
• W2112683927 cites W2105564309 @default.
• W2112683927 cites W2116581628 @default.
• W2112683927 cites W2116966343 @default.
• W2112683927 cites W2118617344 @default.
• W2112683927 cites W2125055973 @default.
• W2112683927 cites W2140838251 @default.
• W2112683927 cites W2150745003 @default.
• W2112683927 cites W2167807244 @default.
• W2112683927 doi "https://doi.org/10.1177/2049936114522996" @default.
• W2112683927 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4072046" @default.
• W2112683927 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25165557" @default.
• W2112683927 hasPublicationYear "2014" @default.
• W2112683927 type Work @default.
• W2112683927 sameAs 2112683927 @default.
• W2112683927 citedByCount "1" @default.
• W2112683927 countsByYear W21126839272016 @default.
• W2112683927 crossrefType "journal-article" @default.
• W2112683927 hasAuthorship W2112683927A5037737415 @default.
• W2112683927 hasAuthorship W2112683927A5043271142 @default.
• W2112683927 hasAuthorship W2112683927A5076411219 @default.
• W2112683927 hasAuthorship W2112683927A5078431481 @default.
• W2112683927 hasAuthorship W2112683927A5090269232 @default.
• W2112683927 hasBestOaLocation W21126839271 @default.
• W2112683927 hasConcept C118441451 @default.
• W2112683927 hasConcept C126322002 @default.
• W2112683927 hasConcept C164705383 @default.
• W2112683927 hasConcept C2776331378 @default.
• W2112683927 hasConcept C2776409635 @default.
• W2112683927 hasConcept C2776962512 @default.
• W2112683927 hasConcept C2779703243 @default.
• W2112683927 hasConcept C2780486423 @default.
• W2112683927 hasConcept C2781005686 @default.
• W2112683927 hasConcept C71924100 @default.
• W2112683927 hasConceptScore W2112683927C118441451 @default.
• W2112683927 hasConceptScore W2112683927C126322002 @default.
• W2112683927 hasConceptScore W2112683927C164705383 @default.
• W2112683927 hasConceptScore W2112683927C2776331378 @default.
• W2112683927 hasConceptScore W2112683927C2776409635 @default.
• W2112683927 hasConceptScore W2112683927C2776962512 @default.
• W2112683927 hasConceptScore W2112683927C2779703243 @default.
• W2112683927 hasConceptScore W2112683927C2780486423 @default.
• W2112683927 hasConceptScore W2112683927C2781005686 @default.
• W2112683927 hasConceptScore W2112683927C71924100 @default.
• W2112683927 hasIssue "2" @default.
• W2112683927 hasLocation W21126839271 @default.
• W2112683927 hasLocation W21126839272 @default.
• W2112683927 hasLocation W21126839273 @default.
• W2112683927 hasLocation W21126839274 @default.
• W2112683927 hasOpenAccess W2112683927 @default.
• W2112683927 hasPrimaryLocation W21126839271 @default.
• W2112683927 hasRelatedWork W1970081618 @default.
• W2112683927 hasRelatedWork W1982720702 @default.
• W2112683927 hasRelatedWork W1997206770 @default.
• W2112683927 hasRelatedWork W2006214313 @default.
• W2112683927 hasRelatedWork W2006427735 @default.
• W2112683927 hasRelatedWork W2020542056 @default.
• W2112683927 hasRelatedWork W2028268919 @default.
• W2112683927 hasRelatedWork W2048536129 @default.
• W2112683927 hasRelatedWork W2057436131 @default.
• W2112683927 hasRelatedWork W2058240154 @default.
• W2112683927 hasRelatedWork W2061927735 @default.
• W2112683927 hasRelatedWork W2069545616 @default.
• W2112683927 hasRelatedWork W2126941248 @default.
• W2112683927 hasRelatedWork W2139385036 @default.
• W2112683927 hasRelatedWork W2226830460 @default.
• W2112683927 hasRelatedWork W3133910802 @default.
• W2112683927 hasRelatedWork W3137444763 @default.
• W2112683927 hasRelatedWork W3141561812 @default.
• W2112683927 hasRelatedWork W3194882108 @default.
• W2112683927 hasRelatedWork W2786194130 @default.
• W2112683927 hasVolume "2" @default.
• W2112683927 isParatext "false" @default.
• W2112683927 isRetracted "false" @default.
• W2112683927 magId "2112683927" @default.
• W2112683927 workType "article" @default.